News

ReAlta Life Sciences Further Bolsters Experienced Executive Team with the Appointment of Peter Ho, Ph.D., as Head of Business Development and Corporate Strategy

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced that Peter Ho, Ph.D., has joined the Company as Head of Business Development and Corporate Strategy.

“I am thrilled to have Peter join our executive team at this pivotal time as we advance our three Phase 2 programs in rare and acute inflammatory diseases,” said David Marek, Chief Executive Officer of ReAlta. “Peter’s expertise in business development and corporate strategy, which spans biopharmaceutical companies of all sizes and stages, will be a tremendous asset for ReAlta as we look to maximize opportunities for our platform.”

“ReAlta has key inflection points in the near future across the Company’s three lead clinical programs in hypoxic ischemic encephalopathy (HIE), acute graft-versus-host disease (aGvHD), and acute exacerbations of chronic obstructive pulmonary disease (AE-COPD), as well as a promising and unique platform to generate additional assets with the potential to address huge unmet needs in both acute and chronic inflammatory diseases,” said Dr. Ho. “I look forward to working with Dave and the rest of the ReAlta team to identify opportunities to create value for the company and, most importantly, for patients facing life-threatening diseases.”

Dr. Ho has more than 20 years of biopharmaceutical industry experience. Prior to joining ReAlta, he was Head of Cell Therapy Business Development at Ginkgo Bioworks. He has held senior business development roles at a variety of biotechnology companies, including Nektar Therapeutics, BeiGene, Iovance, and Allergan. Dr. Ho has also led negotiations to execute drug discovery collaborations and clinical development partnerships, as well as license agreements. Earlier in his career, he worked in early-stage drug company investments at D.E. Shaw, in finance as an equity research analyst covering major pharmaceutical companies, as well as in advertising and communications at Grey Healthcare Group. Dr. Ho has an MBA from the UCLA Anderson School of Management, a Ph.D. in biology from the University of California, San Diego, and undergraduate degrees in chemistry and biology from the University of California, Irvine.

Learn more here.

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep